These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294 [TBL] [Abstract][Full Text] [Related]
8. Mutations in gp41 and gp120 of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate. Borkow G; Lara HH; Lapidot A Biochem Biophys Res Commun; 2003 Dec; 312(4):1047-52. PubMed ID: 14651977 [TBL] [Abstract][Full Text] [Related]
9. HIV co-receptors as targets for antiviral therapy. Schols D Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547 [TBL] [Abstract][Full Text] [Related]
10. R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors. Gondois-Rey F; Biancotto A; Fernandez MA; Bettendroffer L; Blazkova J; Trejbalova K; Pion M; Hirsch I J Virol; 2006 Jan; 80(2):854-65. PubMed ID: 16378987 [TBL] [Abstract][Full Text] [Related]
11. Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines. Cassetta L; Fortunato O; Adduce L; Rizzi C; Hering J; Rovere-Querini P; Bianchi ME; Alfano M; Poli G AIDS; 2009 Mar; 23(5):567-77. PubMed ID: 19194273 [TBL] [Abstract][Full Text] [Related]
12. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651 [TBL] [Abstract][Full Text] [Related]
15. CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Penn ML; Grivel JC; Schramm B; Goldsmith MA; Margolis L Proc Natl Acad Sci U S A; 1999 Jan; 96(2):663-8. PubMed ID: 9892690 [TBL] [Abstract][Full Text] [Related]
16. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963 [TBL] [Abstract][Full Text] [Related]
17. A novel colorimetric assay for CXCR4 and CCR5 tropic human immunodeficiency viruses. Kajiwara K; Kodama E; Matsuoka M Antivir Chem Chemother; 2006; 17(4):215-23. PubMed ID: 17066899 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of bacterial RNase P by aminoglycoside-arginine conjugates. Eubank TD; Biswas R; Jovanovic M; Litovchick A; Lapidot A; Gopalan V FEBS Lett; 2002 Jan; 511(1-3):107-12. PubMed ID: 11821058 [TBL] [Abstract][Full Text] [Related]
19. Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites. Berchanski A; Lapidot A J Mol Model; 2009 Mar; 15(3):281-94. PubMed ID: 19057930 [TBL] [Abstract][Full Text] [Related]